Biocon and Quark begin Phase II/III trial of QPI-1007 for ocular neuroprotection

Indian biopharmaceutical firm Biocon and US-based Quark Pharmaceuticals have announced the initiation of the pivotal global Phase II/III trial (QRK207) of siRNA (small interfering RNA) drug candidate, QPI-1007, for ocular neuroprotection.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news